Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 10,535 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Not applicable Interventional

PREPARE: Patient Centered Perioperative Experience

NCT04472117
View directory record Official record
Conditions
Minimally Invasive Surgery (MIS) Hysterectomy
Interventions
usual care, Educational video
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

NCT06632990
View directory record Official record
Conditions
Drug Drug Interaction (DDI)
Interventions
BMS-984923, Midazolam, Caffeine, dextromethorphan
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 2 Interventional

Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

NCT04340882
View directory record Official record
Conditions
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Docetaxel, Pembrolizumab, Ramucirumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Not applicable Interventional

EDX110 Randomized Control Trial for Treatment of DFUs

NCT07209358
View directory record Official record
Conditions
Wound Heal, Diabetic Foot Ulcer
Interventions
EDX110
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Ana, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Sleep and Inflammatory Resolution Pathway

NCT03377543
View directory record Official record
Conditions
Inflammatory Response, Inflammation, Sleep, Sleep Restriction
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

NCT04825743
View directory record Official record
Conditions
ST-elevation Myocardial Infarction (STEMI)
Interventions
zalunfiban, Placebo
Drug
Lead sponsor
CeleCor Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Anchorage, Alaska • Royal Oak, Michigan • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 4 Interventional

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435
View directory record Official record
Conditions
Type 2 Diabetes (T2DM)
Interventions
SGLT-2 inhibitor, GLP1-RA
Drug
Lead sponsor
MaryAnn Banerji
Other
Eligibility
24 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 2 Interventional

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

NCT05524935
View directory record Official record
Conditions
Uveal Melanoma, Ocular Melanoma
Interventions
Pembrolizumab, Olaparib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Not applicable Interventional

Transdermal Vagal Stimulation for POTS

NCT02281097
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
Stimulation, Placebo
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Daratumumab

NCT05438043
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
7
States / cities
Miami, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting No phase listed Observational

HEAL-4: Real-World Effectiveness of 4 Amniotic Allografts Adjunctive to Standard Care in DFU, VLU, and PU

NCT07223515
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Interventions
Not listed
Lead sponsor
Dynamic Medical Services dba Acesso Biologics
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Novi, Michigan • Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 3 Interventional

Atrasentan in Patients With IgA Nephropathy

NCT04573478
View directory record Official record
Conditions
IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions
Atrasentan, Placebo, Zigakibart
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Alhambra, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 2 Interventional

Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device

NCT02600208
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
CliniMACs
Device
Lead sponsor
Julie-An M. Talano
Other
Eligibility
Up to 23 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 2 Interventional Results available

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

NCT04021108
View directory record Official record
Conditions
Gastroesophageal Adenocarcinoma
Interventions
Nivolumab 240 MG
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
5
States / cities
Tampa, Florida • St Louis, Missouri • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Not applicable Interventional

A Clinical Study to Evaluate the Effects of a Supplement on Cognitive Function

NCT07883525
View directory record Official record
Conditions
Cognition Improvement, Cognition Function
Interventions
Necternal Supplement, Placebo
Dietary Supplement
Lead sponsor
Necternal LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Not applicable Interventional Results available

Cervical Spondylotic Myelopathy Surgical Trial

NCT02076113
View directory record Official record
Conditions
Cervical Spondylosis With Myelopathy
Interventions
Ventral (Front) decompression with Fusion, Dorsal (Back) Decompression with Fusion, Dorsal (back) Laminoplasty
Procedure
Lead sponsor
Lahey Clinic
Other
Eligibility
45 Years to 80 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
15
States / cities
San Francisco, California • Atlanta, Georgia • Kansas City, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 3 Interventional

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

NCT03533582
View directory record Official record
Conditions
Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Patient Observation, Resection, Sorafenib, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
180
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 134 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting No phase listed Observational

Parental Decision-Making for Children With Relapsed Neuroblastoma

NCT02282735
View directory record Official record
Conditions
Relapsed Neuroblastoma
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting No phase listed Observational

LAMBDA 002 (Lung Registry) Study

NCT05170425
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Prospera
Device
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
California City, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation

NCT07221760
View directory record Official record
Conditions
Dentatorubral-Pallidoluysian Atrophy
Interventions
nL-ATN1-001
Drug
Lead sponsor
n-Lorem Foundation
Other
Eligibility
22 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Not applicable Interventional

Remote Game-based Exercise Program for Cognitive and Motor Function Improvement

NCT05235113
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Cognitive Impairment, Memory Loss
Interventions
Tele-Exergame Platform, No Tele-Exergame Platform
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
55 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Distinct Nebraska-Dry Bean Market Classes on Gut Microbiota

NCT06935435
View directory record Official record
Conditions
Dietary Intervention, Gut Microbiota
Interventions
Pink Beans, Great Northern Beans, Five-Bean Mixture
Other
Lead sponsor
University of Nebraska Lincoln
Other
Eligibility
19 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 1 Interventional

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

NCT01829568
View directory record Official record
Conditions
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
Interventions
Ibrutinib, Lenalidomide, Rituximab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 15, 2026, 4:40 AM EST
Active, not recruiting Phase 3 Interventional

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

NCT07216482
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Enlicitide, Rosuvastatin, Placebo for Enlicitide, Placebo for Rosuvastatin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Birmingham, Alabama • Foley, Alabama • Phoenix, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 15, 2026, 4:40 AM EST